Sugi Predict

Sugi Predict / Compounds / SCHEMBL19209536

SCHEMBL19209536

SCHEMBL19209536

COc1ccc2c(CC(C)N)c[nH]c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 4/20 0.81
▸ HTR1A P08908 2/20 0.81
▸ HTR2C P28335 2/20 0.81
▸ HTR2B P41595 2/20 0.81
▸ MEN1 O00255 1/20 0.65
▸ KMT2A Q03164 1/20 0.65
▸ HTR6 P50406 2/20 0.60
▸ ADRB1 P08588 1/20 0.60
▸ ADRA2A P08913 1/20 0.60
▸ SLC6A2 P23975 1/20 0.60
▸ HTR1D P28221 1/20 0.60
▸ HTR1B P28222 1/20 0.60
▸ HTR1E P28566 1/20 0.60
▸ SLC6A4 P31645 1/20 0.60
▸ HTR7 P34969 1/20 0.60
▸ SLC6A3 Q01959 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9773007 0.90 HTR2A (1.00) HTR2AHTR1AHTR2CHTR2BMEN1
SCHEMBL29365282 0.90 HTR2A (1.00) HTR2AHTR1AHTR2CHTR2BMEN1
SCHEMBL130876 0.90 HTR2A (1.00) HTR2AHTR1AHTR2CHTR2BMEN1
SCHEMBL9773017 0.90 HTR2A (1.00) HTR2AHTR1AHTR2CHTR2BMEN1
SCHEMBL25769074 0.89 HTR2A (0.65) HTR2AHTR1AHTR2CHTR2BMEN1
SCHEMBL7997808 0.87 HTR2A (0.62) HTR2AHTR1AHTR2CHTR2BMEN1
SCHEMBL1460679 0.84 KMT2A (0.61) HTR2AHTR1AHTR2CHTR2BMEN1
SCHEMBL18029114 0.84 KMT2A (0.61) HTR2AHTR1AHTR2CHTR2BMEN1
SCHEMBL1460676 0.84 KMT2A (0.61) HTR2AHTR1AHTR2CHTR2BMEN1
SCHEMBL10956670 0.84 SCN9A (0.65) HTR2AHTR1AHTR2CHTR2BMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12187736-B2 Selective estrogen receptor degraders and uses thereof INVENTISBIO LLC (US) 2025-01-07 — — US disclosed
US-20240043442-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF INVENTISBIO LLC 2024-02-08 — — US disclosed
US-20210253592-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF INVENTISBIO LLC (US) 2021-08-19 — — US disclosed
US-20210253592-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF INVENTISBIO LLC (US) 2021-08-19 — — US disclosed
CN-113004273-A Selective estrogen receptor degradants and uses thereof 益方生物科技(上海)股份有限公司 2021-06-22 — — CN disclosed
US-11014936-B2 Selective estrogen receptor degraders and uses thereof INVENTISBIO LLC (US) 2021-05-25 — — US disclosed
CN-109362222-B Selective estrogen receptor degradants and uses thereof 益方生物科技(上海)股份有限公司 2021-03-19 — — CN disclosed
EP-3411034-B1 SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF INVENTISBIO INC (KY) 2020-11-25 — — EP disclosed
EP-3411034-B1 SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF INVENTISBIO INC (KY) 2020-11-25 — — EP disclosed
US-10647724-B2 Selective estrogen receptor degraders and uses thereof INVENTISBIO INC. (KY) 2020-05-12 — — US disclosed
US-10647724-B2 Selective estrogen receptor degraders and uses thereof INVENTISBIO INC. (KY) 2020-05-12 — — US disclosed
US-20200048250-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF INVENTISBIO LLC 2020-02-13 — — US disclosed
US-20200040001-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF INVENTISBIO LLC 2020-02-06 — — US disclosed
US-20200040001-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF INVENTISBIO LLC 2020-02-06 — — US disclosed
EP-3411034-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF Inventisbio Inc. (KY) 2018-12-12 — — EP disclosed
WO-2017136688-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF INVENTISBIO INC. (KY) 2017-08-10 — — WO disclosed
WO-2017136688-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF INVENTISBIO INC. (KY) 2017-08-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048250-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF ESR1, ESRRA, ESR2 HTR2A 704/4885HTR1A 870/4885HTR2C 699/4885
US-12187736-B2 Selective estrogen receptor degraders and uses thereof ESR1, ESRRA, ESR2 HTR2A 704/4885HTR1A 870/4885HTR2C 699/4885
US-20240043442-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF ESR1, ESRRA, ESR2 HTR2A 704/4885HTR1A 870/4885HTR2C 699/4885
US-20210253592-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF ESR1, ESRRA, ESR2 HTR2A 704/4885HTR1A 870/4885HTR2C 699/4885
US-10647724-B2 Selective estrogen receptor degraders and uses thereof ESR1, ESRRA, ESR2 HTR2A 704/4885HTR1A 870/4885HTR2C 699/4885
US-20200040001-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF ESR1, ESRRA, ESR2 HTR2A 704/4885HTR1A 870/4885HTR2C 699/4885
US-11014936-B2 Selective estrogen receptor degraders and uses thereof ESR1, ESRRA, ESR2 HTR2A 704/4885HTR1A 870/4885HTR2C 699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.